Mean Ocular Surface Disease Index (OSDI) scores (total score and scores for the 3 subscales) by disease severity based on the physician's assessment (left) and the composite score (right). Lissamine green scoring was unavailable for 1 patient, preventing the computation of a composite score.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and Validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615–621. doi:10.1001/archopht.118.5.615
Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To evaluate the validity and reliability of the Ocular Surface Disease Index (OSDI) questionnaire.
Participants (109 patients with dry eye and 30 normal controls) completed the OSDI, the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), the McMonnies Dry Eye Questionnaire, the Short Form-12 (SF-12) Health Status Questionnaire, and an ophthalmic examination including Schirmer tests, tear breakup time, and fluorescein and lissamine green staining.
Factor analysis identified 3 subscales of the OSDI: vision-related function, ocular symptoms, and environmental triggers. Reliability (measured by Cronbach α) ranged from good to excellent for the overall instrument and each subscale, and test-retest reliability was good to excellent. The OSDI was valid, effectively discriminating between normal, mild to moderate, and severe dry eye disease as defined by both physician's assessment and a composite disease severity score. The OSDI also correlated significantly with the McMonnies questionnaire, the National Eye Institute Visual Functioning Questionnaire, the physical component summary score of the Short Form-12, patient perception of symptoms, and artificial tear usage.
The OSDI is a valid and reliable instrument for measuring the severity of dry eye disease, and it possesses the necessary psychometric properties to be used as an end point in clinical trials.
DRY EYE DISEASE is one of the most frequently encountered categories of ocular morbidity in the United States, with as many as 4.3 million persons older than 65 years suffering from symptoms either often or all of the time.1,2 The National Eye Institute workshop on clinical trials in dry eye defined dry eye as "a disorder of the tear film due to tear deficiency or excessive tear evaporation which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort."3 This workshop noted that a dry eye condition can exist without evidence of ocular surface damage and that a primary goal of treatment should be to improve symptoms. Moreover, the workshop participants concluded that all clinical trials concerning dry eye should include an assessment of subjective symptoms and functional lifestyle through the use of a well-designed and validated questionnaire, and that such an instrument may be the best measure for determining the clinical efficacy of therapeutic interventions.
To date, the McMonnies Dry Eye Questionnaire is the only patient-perspective instrument specific for dry eye disease that has a formalized grading scheme and some published psychometric properties.4,5 However, this instrument was evaluated as a screening test to discriminate subjects with dry eye from a normal population and not as an instrument to grade either dry eye symptom severity or its effect on vision-related function. In addition, formal reliability testing on this instrument has not been published. Bandeen-Roche et al6 developed a 6-item symptom inventory for population-based epidemiological research. However, they did not include a numeric grading scheme that easily summarizes a patient's reported severity. Moreover, the reported Cronbach α for this symptom inventory (0.61) suggests that its internal consistency may not be high enough for groupwise comparisons.7
The Ocular Surface Disease Index (OSDI), developed by the Outcomes Research Group at Allergan Inc (Irvine, Calif),8 is a 12-item questionnaire designed to provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning. The initial OSDI items were generated from patient comments from several years of clinical studies conducted by Allergan Inc, several quality-of-life instruments, and suggestions from clinical investigators. This item list was then distributed to more than 400 patients with dry eye disease, who were asked to indicate whether they experienced any of the symptoms or problems on the list and, if so, how often. This information was combined with responses from 44 patients with dry eye disease and 2 health professionals who were asked to list aspects of their dry eye condition that affected their daily activities. Item responses were then categorized, and categories mentioned more than once were formatted into an initial questionnaire. This initial questionnaire included 40 items, which were later reduced to the final 12 questions on the basis of validity and reliability data from 3 groups (2 small groups of patients with dry eye and one phase II clinical trial group).
The objective of the present study was to evaluate the validity and reliability of the OSDI and to determine its usefulness as an end point in clinical trials testing the efficacy of new treatments for dry eye disease.
This study was conducted in compliance with the Code of Federal Regulations for institutional review boards, sponsors, and investigator obligations. Written informed consent was obtained from all patients before enrollment in the study.
Patients 18 years or older who had been diagnosed as having dry eye symptoms (International Classification of Diseases, Ninth Revision,9 code 375.15) at the Henry Ford Health System in the preceding 12 months and who had had symptoms for at least 3 months were recruited for the study. Any patients who had undergone temporary or permanent punctal occlusion were eligible 3 months after the procedure. Control subjects had to have no significant ocular disease other than refractive error and no systemic disease likely to be associated with dry eye. Control subjects were sex-matched and age-matched (± 5 years) to the patients with dry eye disease.
Any patient who had any uncontrolled systemic disease or disability that affected his or her activities of daily living (including ocular allergy, infection, or irritation that was not related to dry eye disease) was excluded from participation in the study. Also excluded were patients who had undergone ocular surgery (including cataract surgery) within the previous 6 months or who were known to have an allergy to any component of any of the agents used in the study, eg, lissamine green, fluorescein, or anesthetic.
All study participants had to have a life expectancy of 1 year or more and "walking-around" visual acuity (with their usual correction) of 20/40 or better in each eye. They had to be English-speaking and cognitively intact (score of ≥20 on the Folstein Mini-Mental State Examination).10
Eligible participants completed a series of questionnaires in which their sociodemographic status, health status, visual functioning, and ocular symptoms were assessed. After completion of the questionnaires, patients underwent a detailed ophthalmic examination. Questionnaires were completed before the examination to ensure that the clinical encounter would not influence the patients' responses. To determine test-retest reliability of the OSDI, all patients were asked to return in 2 weeks to complete the questionnaire a second time.
Participants completed by self-administration the Short Form-12 Health Survey (SF-12), a measure of general health status11; the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), a questionnaire found to be reliable and valid across several common eye diseases12; the McMonnies Dry Eye Questionnaire5; and the OSDI. They were also asked to record their perception of the severity of their dry eye symptoms (as measured by a 9-level subjective facial expression scale).13 They also completed a medical comorbidity survey.
Clinical measures included "walking-around" binocular visual acuity according to the Early Treatment of Diabetic Retinopathy Study chart; corneal and conjunctival surface staining using fluorescein and lissamine green, graded according to the Van Bijsterveld14 and Oxford scoring schemes, respectively; tear production according to Schirmer test type 1 (with no anesthesia), Schirmer test type 2 (with nasal stimulation) for those with no tear production on Schirmer test type 1, and basic secretor's test (with anesthesia); and tear quality (using tear breakup time). The presence of blepharitis, meibomian gland dysfunction, ocular mucin, lid abnormalities, and ocular surface disorders was recorded as well (based on the physician's judgment). The severity of dry eye disease was assessed in the following 3 ways: by physician assessment, by a composite disease severity score (see below), and by the patients' frequency of artificial tear use.
The composite disease severity score was created to establish a second measure of severity that was substantially less dependent on the physician's subjective assessment and easily reproducible. It also adheres to recommendations of the National Eye Institute Workshop by combining traditional clinical measures of dry eye (Schirmer test type 1 and lissamine green staining) with a symptom-based measure (patient perception of ocular symptoms) in the evaluation of dry eye. The criteria for measuring disease severity based on this composite score were set up a priori and were not modified at any point during the study. First, the patient's findings were designated as normal, mild to moderate, or severe for each individual measure. The cutoff points for the normal and severe groups were based on values suggested by a review of the medical and scientific literature.13-18 However, there was no consensus or consistent trend in the literature indicating appropriate thresholds for distinguishing between patients with mild and moderate values. Therefore, all patients with disease severity graded as greater than normal but less than severe were combined into a single mild to moderate group. The severity designations used for the Schirmer test type 1 were as follows: greater than 10 mm, normal; 6 to 10 mm, mild to moderate; and 0 to 5 mm, severe. The severity designations used for lissamine green staining were as follows: 0 to 1, normal; 2 to 6, mild to moderate; and 7 to 9, severe. The severity designations used for the subjective facial expression scale were as follows: 1 to 3, normal; 4 to 7, mild to moderate; and 8 to 9, severe. A value of 1 was assigned to a normal grade for each measure, 2 for a mild to moderate grade, and 3 for severe. The values for the 3 measures were then summed to generate a final severity score: less than 3, normal; 4 to 7, mild to moderate; and 8 to 9, severe.
The 12 items of the OSDI questionnaire were graded on a scale of 0 to 4, where 0 indicates none of the time; 1, some of the time; 2, half of the time; 3, most of the time; and 4, all of the time. The total OSDI score was then calculated on the basis of the following formula: OSDI=[(sum of scores for all questions answered) × 100]/[(total number of questions answered) × 4].
Thus, the OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability. Subscale scores are computed similarly with only the questions from each subscale used to generate its own score.
The distribution of age, race, sex, income, and educational level between patients with dry eye disease and control patients was compared by t test, χ2 test, or Fisher exact test, where appropriate. A P value of .05 was considered significant. Mean functional status scores were computed for all disease severity categories and the control group. The proportion of patients whose data were at the ceiling and floor in each category was also computed.
Factor analysis with varimax rotation19 was used to determine whether items within the OSDI tended to cluster together to create subscales (eg, visual functioning and ocular symptoms). Scores were computed for identified subscales, and these subscales underwent formal reliability and validity assessment along with the total instrument.
The reliability of the OSDI questionnaire overall, and for the identified subscales within this study, was computed with Cronbach α, a measure of internal consistency. The test-retest reliability of the instrument was evaluated by computing a random-effects intraclass correlation among patients who completed the OSDI a second time.
Discriminant validity of the OSDI was assessed by testing for significant differences in OSDI scores by disease severity (based on both the physician's assessment of severity and the composite disease severity score) by an analysis of variance and the Tukey test for multiple comparisons, which maintains an overall P value of .05. Multiple linear regression was also used to test for an association between disease severity and OSDI scores while adjusting for factors considered likely to influence functional status measures, including sociodemographic factors (age, race, sex, education, income, and employment status) and number of medical comorbidities.
Concurrent validity was computed by correlating OSDI scores with the other measures of health status (McMonnies questionnaire, NEI VFQ-25, and SF-12). In addition, correlations with the traditional objective measures of dry eye disease (including lissamine green and fluorescein staining, tear breakup time, Schirmer scores, and artificial tear usage) in the more severely affected (worse) eye were computed with the Spearman coefficient, a nonparametric statistic, as some of the measures were ordinal.
Finally, receiver operating characteristic (ROC) curves were generated to describe the sensitivity and specificity of the OSDI for the diagnosis of dry eye at each OSDI score with the use of both the physician's assessment of severity and the composite disease severity score.20
A target enrollment of 150 patients was selected to detect a correlation coefficient of 0.23, detectable with a power of 0.80 at an α level of .05. For estimating test-retest reliability, a sample size of 50 patients was deemed sufficient to provide a 1-sided 95% confidence interval of 0.84 (lower bound) for an intraclass correlation of 0.90.21 However, to increase the power of the estimate of test-retest reliability, all patients were asked to return for a second test.
There were 109 patients with dry eye disease and 30 control subjects. There were no statistically significant differences between the patient and control groups in the following demographic variables: age, sex, race, education level, employment, and income. The mean ages for subjects in the control and dry eye groups were approximately 55 and 58 years, respectively, with the majority being female and white. As expected, patients with dry eye had more associated medical and concomitant ocular disorders than the control patients (Table 1).
All 139 subjects who were enrolled in the study completed the first visit; 76 subjects returned for a retest visit. Some patients recruited as control subjects were found to have signs and symptoms of dry eye disease on the basis of either the physician's assessment of severity or the composite disease severity score and were analyzed accordingly. Two patients recruited as control subjects reported a history of rheumatoid arthritis at the time of the examination but were analyzed as controls on the basis of the physician's assessment and the computed composite score. If these subjects actually had unrecognized dry eye, the resulting bias would have been a conservative one and reduced the observed differences between the diseased and control groups.
Factor analysis disclosed that there were 3 subscales, interpreted as vision-related function (6 questions), ocular symptoms (3 questions), and environmental triggers (3 questions).
The Cronbach α for the overall instrument and each of the subscales ranged from good to excellent (Table 2), and all exceeded the 0.7 that is recommended for group analyses.7 The intraclass correlation between the test and retest scores was also good to excellent for both the total OSDI score and the subscales (Table 2) and once again met or exceeded 0.7.
When patients were grouped according to the physician's assessment of severity, the mean OSDI total score was 36 in the severe group, 21 in the mild to moderate group, and 10 in the control group (Figure 1, left; Table 3). The proportion of patients with scores at the ceiling and floor in each category can also be seen in Table 3. All between-group differences were statistically significant (P≤.05; Tukey test for multiple comparisons) with the exception of the comparison between the normal and mild to moderate groups for the vision-related function subscale, and the mild to moderate and severe groups for the environmental triggers subscale.
When patients were grouped according to composite disease severity scores, the mean OSDI scores were 36 in the severe group, 18 in the mild to moderate group, and 5 in the control group (Figure 1, right; Table 3). The proportion of patients with scores at the ceiling and floor in each category can also be seen in Table 3. All groupwise comparisons (between the scores for the normal, mild to moderate, and severe groups) for the total OSDI score and each subscale of the OSDI were statistically significant (P≤.05; Tukey test for multiple comparisons).
The OSDI total score and each of the subscale scores were also significantly associated with disease severity (as measured by either the physician's assessment or the composite score) in multivariate analyses adjusting for sociodemographic factors (age, race, sex, education, income, and employment status) and number of medical comorbidities (P≤.005).
In comparing disease severity based on the physician's assessment with that determined by the composite score, it was found that 130 of 139 patients were graded within 1 level of each other. The weighted κ, which is a measure of agreement between 2 rating scales,21 was 0.61, reflecting good agreement. However, patients' symptoms tended to be designated as slightly less severe according to the physician's assessment than they were on the basis of the composite disease severity score.
The correlation coefficients between the OSDI and tear breakup time, Schirmer test type 1, fluorescein staining, and lissamine green staining were very low when all subjects were analyzed together (Table 4). However, when the analysis focused on only patients with Schirmer test type 1 scores less than 10 mm, low to moderate statistically significant correlations were detected for all subscales except vision-related function (Table 4).
In contrast, there was a stronger correlation between OSDI scores and patient-reported variables. All OSDI scores showed moderate correlations with the Patient Perception of Ocular Symptoms that were highly statistically significant (P<.001) (Table 5). There was also a moderate and statistically significant correlation between patient-reported artificial tear usage and both the total OSDI score and all of the OSDI subscales (P<.001) (Table 5). The mean frequency with which patients used artificial tears ranged from 0 to 9 times a day.
There were also moderate correlations between each of the OSDI scores and the McMonnies Dry Eye Questionnaire; all correlations were highly statistically significant (P<.001) (Table 5).
Both the total OSDI score and the scores for the 3 subscales were significantly correlated with the NEI VFQ-25 score (P<.001) (Table 5). The negative correlations obtained reflect the fact that higher scores on the OSDI represent greater disease impact, while higher scores on the NEI VFQ-25 reflect less disability. Correlations between each of the OSDI scores and the NEI VFQ-25 questionnaire were stronger than those between the OSDI and either the McMonnies Dry Eye Questionnaire or the patient perception of ocular symptoms.
The OSDI was also compared with the SF-12, a general measure of health status (Table 5). There were low to moderate correlations between OSDI scores and the physical component summary score of the SF-12 (ρ=−0.39; P<.001); however, the correlations between OSDI scores and the mental component summary score were poor.
The sensitivity and specificity of the OSDI are shown in Table 6. The sensitivity value expresses the proportion of patients above the given threshold who have dry eye, while the specificity value expresses the proportion of patients below the given threshold who do not have dry eye. For the computations presented in Table 6, a threshold was selected that maximized the sum of the sensitivity and specificity values. Alternative thresholds could be chosen that would selectively maximize either the sensitivity or the specificity, depending on how the instrument is to be used. As expected, the performance of the OSDI improved as it was used to discriminate more severe disease. The ROC curves can also be used to describe the performance of a test by plotting the sensitivity vs (1 − specificity) for each possible test result. The area under the ROC curve can be thought of as a summary measure for these curves, with 0.5 indicating that the test is no better than chance at predicting dry eye disease and 1.0 indicating a perfect test for dry eye. The areas under the ROC curve for the OSDI demonstrate good to excellent discrimination with the instrument (Table 6).
In the present study, the OSDI demonstrated both high internal consistency (the Cronbach α for the overall instrument and each of the subscales ranged from good to excellent) and good to excellent test-retest reliability in a large sample of patients with dry eye disease and normal controls. The OSDI also demonstrated excellent validity, effectively discriminating between normal, mild to moderate, and severe dry eye disease as defined by both the physician's assessment of severity and a composite disease severity score. Moreover, the OSDI demonstrated good sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease.
One of the assumptions of test-retest reliability assessments is that the subject's condition has remained stable between the time of the first test and the time of the retest. However, the symptoms of patients with dry eye disease typically fluctuate, thus violating this assumption of stability. This may explain the modest decrease in the test-retest reliability compared with Cronbach α and may be unavoidable with this population. Despite this, the test-retest correlation still meets or exceeds the level recommended for group comparisons of 0.7.7
The OSDI scores correlated well with other eye-specific health status measures, such as the McMonnies questionnaire and the NEI VFQ-25. The correlation was not perfect, however, indicating that the OSDI captures unique aspects of dry eye disease not addressed by these other instruments. This is to be expected, considering the difference in the contents and structure of these different questionnaires. The OSDI is specific for dry eye disease and asks patients the frequency of specific symptoms and their impact on vision-related functioning. The McMonnies questionnaire, although also specific for dry eye disease, was designed as a screening test to discriminate patients with dry eye disease from a normal population5 and primarily uses dichotomous responses (yes or no) to assess the presence of symptoms. The NEI VFQ-25 surveys general ocular health18 and is not intended to capture the broad range of symptoms unique to a certain ocular disorder.
When the results from all patients were analyzed together, OSDI scores did not correlate well with traditional objective clinical measures of dry eye (such as Schirmer test type 1). This is consistent with previous studies that also failed to find strong correlations between objective clinical signs of dry eye and patient symptoms.3 This lack of correlation may be because, among a heterogeneous group of patients with dry eye, these measures lack sufficient sensitivity to capture the full range of ocular surface and tear abnormalities that produce typical dry eye symptoms. However, in certain subsets of patients, these clinical measures may correlate more closely with patient perception of disease severity. In support of this, the present study found that the OSDI correlated moderately with clinical signs among patients with dry eye disease who had tear deficiency.
The OSDI is, therefore, a unique instrument able to assess both the frequency of dry eye symptoms and their impact on vision-related functioning. The OSDI has good to excellent reliability, validity, sensitivity, and specificity. It should prove a valuable complement to other clinical and subjective measures of dry eye disease by providing a quantifiable assessment of dry eye symptom frequency and the impact of these symptoms on vision-related functioning. It also has the necessary psychometric properties to be used as an end point in clinical trials of dry eye disease.
Accepted for publication December 10, 1999.
This study was supported by an unrestricted grant from Allergan Inc, Irvine, Calif. None of the non-Allergan authors have any financial interest in Allergan Inc.
Reprints: Rhett M. Schiffman, MD, MS, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202 (e-mail: email@example.com).
Create a personal account or sign in to: